MUC1-C DEPENDENCY IN DRUG RESISTANT HR+/HER2- BREAST CANCER IDENTIFIES A NEW TARGET FOR TREATMENT WITH AN ANTIBODY-DRUG CONJUGATE
MUC1-C is a common effector of treatment resistant HR+/HER2- BC cells and is a potential target for their treatment Overall design: RNA Seq in HR+/HER2- Cell lines with doxicicline inducible MUC1-C shRNA silencing